Back to Top
[0]
Enews Now
November 2017
0
In the News
Kimberly G. Blumenthal, MD, MSc, along with a team of researchers at Massachusetts General Hospital estimated the cost of penicillin allergy evaluation for unverified penicillin-allergic patients.
News Briefs
Meet the New AAAAI Website and Social Media Medical Editors
The AAAAI is excited to welcome the editors and continue to grow our online presence. Read more »
You Have Three Days to Submit Your Late Breaking Abstract
Late breaking abstract submission for the 2018 AAAAI/WAO Joint Congress closes in a few days. Submit your research before it’s too late. Read more »
Advance Your Emerging Career in Research
We’re looking for the best and brightest young researchers to attend the 2018 AAAAI Hypersensitivity Summer School. Read more »
Web Tips

AAAAI Virtual Allergist™

The AAAAI Virtual Allergist, also known as the symptom checker, has been updated to include additional symptoms and links to patient articles in the Conditions & Treatments Library. Be sure to point your patients to this tool on the AAAAI’s website.

Join the AAAAI and Allergic Living Holiday Twitter Chat on November 14

The AAAAI is excited to host another Twitter chat with Allergic Living magazine. Join us November 14 at 11:00 am CT with the hashtag #allergyready. For one hour, we will be engaging families who want to learn more about allergies and asthma as they gear up for the holiday season. Topics will include holiday visits, surprising triggers and winter asthma issues. We will be exchanging our favorite allergy friendly recipes after the chat, so come prepared with your best treats.

From the President

Dear Colleagues,

The AAAAI has completed the first step in our ongoing evaluation of the role of allergy/immunology (A/I) in the healthcare system and development of a strategy to ensure we have a seat at the table. This first step was the Summit for the Future of Allergy and Immunology, which took place October 19-22 in Washington, DC. It went very well and, as expected, there was a great deal of productive discussion.

While there are a number of challenges, we have identified opportunities for A/I in our continually evolving healthcare system if we seize the opportunity. The AAAAI has laid the groundwork in several important ways, including:

  • investing in a registry
  • communicating with experts in healthcare finance to determine how reimbursement can be maximized in population management, particularly of high risk populations
  • exploring ways to obtain objective data that demonstrates that A/I has better outcomes in asthma, drug hypersensitivity, immune deficiency, urticaria, anaphylaxis, and food allergy (an area in which we are uniquely qualified).